(Case 5 A ) c g>a Exon 24 splice acceptor Splicing defect - Splicing defect

Similar documents
Supplementary material

Supplementary Table 2. Identified causative mutations and/or mutation candidates.

Supplementary Document

CHAPTER IV RESULTS Microcephaly General description

Mutational and phenotypical spectrum of phenylalanine hydroxylase deficiency in Denmark

The coiled-coil domain containing protein CCDC40 is essential for motile cilia function and left-right axis formation

Deciphering Developmental Disorders (DDD) DDG2P

WDR62 is associated with the spindle pole and mutated in human microcephaly

Whole exome sequencing as a first line test: Is there even a role for metabolic biochemists in the future?

Spectrum of mutations in monogenic diabetes genes identified from high-throughput DNA sequencing of 6888 individuals

Clinical Genetics. Functional validation in a diagnostic context. Robert Hofstra. Leading the way in genetic issues

Supplemental Data. De Novo Truncating Mutations in WASF1. Cause Intellectual Disability with Seizures

THE UMD TP53 MUTATION DATABASE UPDATES AND BENEFITS. Pr. Thierry Soussi

Mapping by recurrence and modelling the mutation rate

6/12/2018. Disclosures. Clinical Genomics The CLIA Lab Perspective. Outline. COH HopeSeq Heme Panels

Supplementary Table 1. PIK3CA mutation in colorectal cancer

Spectrum and Classification of ATP7B Variants in a Large Cohort of Chinese Patients with Wilson s Disease Guides Genetic Diagnosis

Supplementary Online Content

Supplementary Figure 1

Reporting TP53 gene analysis results in CLL

Belgian study into von Willebrand Disease (B-Will): First results

Genetic Testing and Analysis. (858) MRN: Specimen: Saliva Received: 07/26/2016 GENETIC ANALYSIS REPORT

July 2015 Assay ID Assay Name Gene COSMIC ID Amino acid change Nucleotide change Wild type allele (VIC label) Mutant allele (FAM label)

Nature Genetics: doi: /ng Supplementary Figure 1. Country distribution of GME samples and designation of geographical subregions.

Clinical utility of the functional mrna evaluation of rare genetic variants in diagnostic practice

BIOCHEMICAL AND MOLECULAR HETEROGENEITY IN CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY

p.r623c p.p976l p.d2847fs p.t2671 p.d2847fs p.r2922w p.r2370h p.c1201y p.a868v p.s952* RING_C BP PHD Cbp HAT_KAT11

Nature Genetics: doi: /ng Supplementary Figure 1. Alternative splicing events in the 5K panel.

Identifying Mutations Responsible for Rare Disorders Using New Technologies

SUPPLEMENTARY INFORMATION. Rare independent mutations in renal salt handling genes contribute to blood pressure variation

NGS panels in clinical diagnostics: Utrecht experience. Van Gijn ME PhD Genome Diagnostics UMCUtrecht

Merging single gene-level CNV with sequence variant interpretation following the ACMGG/AMP sequence variant guidelines

Supplementary Information

Belgian-Czech cooperation in the Brno-VWD study

Whole Exome Sequenced Characteristics

Mutation Detection and CNV Analysis for Illumina Sequencing data from HaloPlex Target Enrichment Panels using NextGENe Software for Clinical Research

Nature Genetics: doi: /ng Supplementary Figure 1

Genotype-Phenotype in Egyptian Patients with Nephropathic Cystinosis. (December 2012 report)

Nature Medicine doi: /nm.2860

Chromosome 15 Chromosome 17 Chromosome 20

Analysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers

Using large-scale human genetic variation to inform variant prioritization in neuropsychiatric disorders

p.arg119gly p.arg119his p.ala179thr c.540+1g>a c.617_633+6del Prediction basis structure

Names for ABO (ISBT 001) Blood Group Alleles

Implementation of the DDD/ClinGen OGT (CytoSure v3) Microarray

Nature Genetics: doi: /ng Supplementary Figure 1. TNFAIP3-associated haplotypes in family 1.

A Natural History Study of Subjects with X-linked Retinoschisis in Anticipation of a Phase I/II Gene Therapy Trial

The Complexity of Simple Genetics

Home Brewed Personalized Genomics

Key determinants of pathogenicity

CentoXome FUTURE'S KNOWLEDGE APPLIED TODAY

CITATION FILE CONTENT/FORMAT

Supplemental Table 1. The list of variants with their respective scores for each variant classifier Gene DNA Protein Align-GVGD Polyphen-2 CADD MAPP

Using the Bravo Liquid-Handling System for Next Generation Sequencing Sample Prep

Variant interpretation using the ACMG-AMP guidelines

Welcome to the Genetic Code: An Overview of Basic Genetics. October 24, :00pm 3:00pm

Truncation and microdeletion of EVC accompanied by novel EFCAB7 missense mutation in Ellis-van Creveld syndrome with atypical congenital heart defect

CHR POS REF OBS ALLELE BUILD CLINICAL_SIGNIFICANCE

Flexible gene panels are essential for personalised genetic testing

MSI positive MSI negative

Nature Neuroscience: doi: /nn Supplementary Figure 1. Missense damaging predictions as a function of allele frequency

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider

Molecular Diagnosis of Genetic Diseases: From 1 Gene to 1000s

Whole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute

Supplementary Figure 1

Challenges of CGH array testing in children with developmental delay. Dr Sally Davies 17 th September 2014

Concurrent Practical Session ACMG Classification

Familial exudative vitreoretinopathy (FEVR) is an inheritable

Genetic Counselling in relation to genetic testing

Variant Annotation and Functional Prediction

SUPPLEMENTARY INFORMATION

Supplementary Table e1. Clinical and genetic data on the 37 participants from the WUSM

Nature Structural & Molecular Biology: doi: /nsmb Supplementary Figure 1

Investigating rare diseases with Agilent NGS solutions

Putative low penetrance or susceptibility variants: sodium channel genes in painful neuropathy as an example

Molecular Diagnostic Laboratory 18 Sequencing St, Gene Town, ZY Tel: Fax:

CentoXome FUTURE'S KNOWLEDGE APPLIED TODAY

Beta Thalassemia Sami Khuri Department of Computer Science San José State University Spring 2015

NGS for Cancer Predisposition

Rapid testing and prenatal diagnosis for at-risk couples presenting during pregnancy without a diagnosis

Dr. Ayman Mohsen Mashi, MBBS Consultant Hematology & Blood Transfusion Department Head, Laboratory & Blood Bank King Fahad Central Hospital, Gazan,

Novel Heterozygous Mutation in YAP1 in A Family with Isolated Ocular Colobomas

Beta Thalassemia Case Study Introduction to Bioinformatics

Supplementary Methods

CHROMOSOMAL MICROARRAY (CGH+SNP)

LTA Analysis of HapMap Genotype Data

Identification of a novel in-frame de novo mutation in SPTAN1 in intellectual disability and pontocerebellar atrophy

Figure S2. Distribution of acgh probes on all ten chromosomes of the RIL M0022

Generating Spontaneous Copy Number Variants (CNVs) Jennifer Freeman Assistant Professor of Toxicology School of Health Sciences Purdue University

Nature Genetics: doi: /ng Supplementary Figure 1

The common colorectal cancer predisposition SNP rs at chromosome 8q24 confers potential to enhanced Wnt signaling

Supplemental Information For: The genetics of splicing in neuroblastoma

Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in lateonset Pompe disease patients

SUPPLEMENTARY INFORMATION

UvA-DARE (Digital Academic Repository) Familial hypercholesterolemia: the Dutch approach Huijgen, R. Link to publication

The Role of Next Generation Sequencing in Solid Tumor Mutation Testing

Variant Detection & Interpretation in a diagnostic context. Christian Gilissen

CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi

Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer

Psych 3102 Lecture 3. Mendelian Genetics

Transcription:

Supplementary table S1. Pathogenic potential of identified DYNC2H1 mutations Family Nucleotide Change Mutation GERP PhyloP SIFT PolyPhen-2 Mutation Taster JATD-1 c. 90443A>G p.d3015g 6.17 5.3 Tolerated Prob damaging (0.995) Disease causing (0.997) (Case 4 A ) c. 1306G>T p.e436* - - - - - JATD-2 c.9044a>g p.d3015g 6.17 5.3 Tolerated Prob damaging (0.995) Disease causing (0.997) (Case 5 A ) c.3459-1g>a Exon 24 splice acceptor 5.56 6.0 Splicing defect - Splicing defect JATD-3 c.9817c>t p.e3273* - - - - - (Case 6, 7 A ) c.7442g>a p.r2481q 5.8 3.9 Tolerated Benign (0.040) Polymorphism (0.78) JATD-4 c.1306g>t p.e436* - - - - - UCL47 c.8457a>g p.i2819m -0.39 0.04 Deleterious Prob damaging (0.954) Disease causing (0.97) JATD-5 c.3682c>a p.l1228i -1 0.3 Tolerated Prob damaging (0.973) Disease causing (0.8) UCL61 c.7663g>a p.v2555m 5.73 3.0 Tolerated Poss damaging (0.476) Polymorphism (0.8) c.7718a>g p.y2573c 6.0 4.2 Tolerated Prob damaging (0.917) Disease causing (0.995) JATD-6 14kb deletion (g.103191405-103204921) p.g3891_q4020del - - - - - c.9044a>g p.d3015g 6.17 5.3 Tolerated Prob damaging (0.995) Disease causing (0.997) c.11437c>t p.r3813c 5.69 4.3 Damaging Prob damaging (1.0) Disease causing (0.999) JATD-7 c.10163c>t p.p3388l 4.78 5.9 Deleterious Prob damaging (0.961) Disease Causing (0.997) UCL19 c.12480_13556del (g.103325916-103350592) p.n4160_q4314del - - - - - JATD-8 c.3719t>c p.i1240t 4.32 5.0 Deleterious Poss damaging (0.803) Disease causing (0.964) UCL 63 c.12716t>g p.l4239r 4.47 4.3 Damaging (low confidence) Prob damaging (0.846) Disease causing (0.998) JATD-9 c. 11560T>G p.w3854g 4.9 4.4 Tolerated Prob damaging (0.994) Disease causing (0.978) 57809 JATD-10 c.6910g>a p.a2304t 4.13 4.3 Tolerated Benign (0.047) Disease Causing (0.93) UCL15 c.8389_8397 delccagctttg p.p2797_l2799 del - - - - - JATD-11 c.195g>t p.t65t 4.37 5.3 Synonymous; splicing defect - Splicing defect UCL90 c.4135a>g p.m1379v 4.32 2.3 Deleterious Benign (0.127) Polymorphism (0.04), splice donor gained JATD-12 c.312_313delta p.p104pfsx*2 - - - - - UCL48 c.5972t>a p.m1991k 4.47 5.0 Deleterious benign (0.429) Disease Causing (0.99) JATD-13 c.4325g>a p.g1442d 3.65 4.3 Deleterious Prob damaging (0.999) Disease causing (0.997) UCL39 c.1953g>a p.k651k 4.47 2.7 Synonymous; splicing defect - Splicing defect JATD-14 c.988c>t p.r330c 4.04 3.5 Deleterious Unknown Disease causing (0.99) UCL80 JATD-15 c. 7594C>T p.r2532w 4.11 1.2 Tolerated Poss. damag (0.761) Disease causing (0.58) UCL58 JATD-16 c.7437+3a>g Exon 45 splice donor 2.11 1.9 Splicing defect - Splicing defect UCL81 c.7539a>t p.g2513g 3.16 1.9 Synonymous; splicing defect - Splicing defect JATD-17 c.6679a>g p.m2227v -0.83 0.47 Deleterious Benign (0.002) Polymorphism, splice donor gained UCL95 c.12538delc p.l4177ffs*29 - - - - - JATD-18 c.2346-5t>g Exon 17 splice acceptor 2.88 1.0 Splicing defect - Splicing defect UCL62 c.7085a>g p.n2362s 4.13 3.3 Deleterious Poss damaging (0.86) Polymorphism (0.66) JATD-19 UCL109 c.7919t>c p.i2640t 4.77 3.7 Deleterious benign (0.255) Disease causing (0.84) c.2612t>c p.l871p 4.05 4.5 Deleterious Prob damaging (0.987) Disease causing (0.99) A Patient described in J. De Vries et al. 2010. Eur J Pediatr 169:77-88. Prediction software used for missense and splicing defects only, evolutionary conservation is scored at nucleotide level by GERP and PhyloP (HG19 values). A Mutation Taster polymorphism classification indicates a change will be tolerated, rather than a known SNP. 1

Supplementary figure S1 Segregation analysis of DYNC2H1 mutations in JATD families Variants identified in the families screened in this study, with double line indicating consanguineous marriages, black filled symbols indicating affected individuals. All identified variants were consistent with affection status and recessive inheritance pattern. 2

Supplementary figure S2 Depth of sequence coverage across DYNC2H1 using different exome sequencing kits Representative samples of coverage achieved using the different exome sequencing kits (A) Agilent v1 38Mb (DYNC2H1 not targeted by this kit) (B) Agilent v2 50Mb, processed in the Netherlands (C) Nimblegen v3 (D) Agilent v2 50Mb, processed in the UK. The y axis shows the coverage, on a scale of 0-100x density of sequence reads. The heterozygously inherited 3 exon deletion in patient from family JATD-7 is boxed. 3

Supplementary figure S3 Genomic deletion present in family JATD-7 patient Heterozygous deletion of 3 exons (exon 87-90) in DYNC2H1 gene identified by ExomeDepth from exome sequence data. The x-axis shows the chromosome position and the y-axis the ratio between the observed and the expected number of reads mapping to each exon. The grey area shows the 99% confidence interval for this ratio. Exons are marked by red crosses, joined by red lines spanning non-sequenced (nonexonic) regions. 4

Supplementary figure S4 Cross-species amino acid alignment in DYNC2H1 for 21 JATD missense mutations and PAL deletion Sequences used: NP_001073932.1 (H.sapiens), XP_863187.1 (C.lupus), XP_589775.4 (B.taurus), NP_084127.2 (M.musculus), NP_075413.1 (R.norvegicus), XP_417173.2 (G.gallus), XP_002664761.1 (D.rerio), NP_492221.2 (C.elegans). Selected protein sequence are shown only. 5

Supplementary figure S5 DYNC2H1 missense mutations are enriched in functional domains similarly to DNAH5 The DYNC2H1 (upper) and DNAH5 (lower) missense mutation count per window is shown (red line) using a sliding window of non-overlapping 100 amino acids. Fishers exact test was used to calculate the enrichment for mutations per 100 amino acid window, the associated log10 p value is shown by the open circles. The lower dotted line indicates p=0.05 and the higher dotted line indicates p<0.01. A single 100 amino acid window between AAA3 and AAA4 is statistically enriched for DYNC2H1 mutations, with similar findings for DNAH5; DNAH5 also shows a non-significant trend of enrichment at 3 other domains in the N- terminus and the MT-binding stalk domain. However, after correcting for multiple hypothesis testing using the Benjamini-Hochberg False Discovery Rate correction, these values are no longer significant for either protein (corrected p values per window shown by filled triangles). DNAH5 mutations taken from previous reports referred to in the main paper. 6

Supplementary figure S6 Skeletal hallmarks of JATD in DYNC2H1 patients (A-K) Hallmarks of JATD: Representative examples of brachydactyly type D (B, JATD-2 in their 20s has solely short and broad thumbs) and cone shaped epiphyses (D, JATD-9; E, JATD-14) were observed. These were found to be absent in some patients (G, JATD-1 when newborn and A, JATD-1 in their 20s; F, JATD-16), and much less pronounced or certain in others (C, JATD-3 in their 20s has possible short fingers). Typical handlebar clavicles were observed at the newborn stage (H, JATD-1; I, JATD-16) while patients in their 20s displayed a much milder thorax phenotype (J, JATD-2; K, JATD-3). 7

Supplementary figure S7 IFT88 concentrates in distal tips of cilia in DYNC2H1 JATD patient fibroblasts Antibody stainings of fibroblasts derived from patients from JATD-1 and JATD-2 families show IFT-B protein IFT88 often accumulates in ciliary tips, suggesting IFT-A transport is disrupted due to DYNC2H1 mutations in these patients. RPGRIP1L (red) is a marker for the ciliary base, and acetylated α-tubulin (cyan) is a marker of the cilia axoneme. The merged images at the left show IFT88 (green), RPGRIP1L and acetylated α-tubulin; right panels display only IFT88 in the same field. Scale bar, 10 μm. Cilia in Figure 3 (main article) are derived from the whole-field images presented here. 8

Supplementary figure S8 IFT57 concentrates in distal tips of cilia in DYNC2H1 JATD patient fibroblasts Antibody stainings of fibroblasts derived from patients from JATD-1 and JATD-2 families show IFT-B protein IFT57 often accumulates in ciliary tips, suggesting IFT-A transport is disrupted due to DYNC2H1 mutations in these patients. RPGRIP1L (red) is a marker for the ciliary base, and acetylated α-tubulin (purple) is a marker of the cilia axoneme. The merged images at the left show IFT57 (green), RPGRIP1L and acetylated α-tubulin; right panels display only IFT57 in the same field. Scale bar, 10 μm. Cilia in Figure 3 (main article) are derived from the whole-field images presented here. 9

UK10K RARE Consortium Saeed Al-Turki 1, 2 Carl Anderson 1 Dinu Antony 3 Inês Barroso 1 Phil Beales 3 Jamie Bentham 4 Shoumo Bhattacharya 4 Keren Carss 1 Krishna Chatterjee 5 Sebhattin Cirak 6 Catherine Cosgrove 4 Petr Danecek 1 Richard Durbin 1 David Fitzpatrick 7 Jamie Floyd 1 Reghan A. Foley 6 Chris Franklin 1 Marta Futema 8 Steve E. Humphries 8 Matt Hurles 1 Chris Joyce 1 Shane McCarthy 1 Hannah M. Mitchison 3 Dawn Muddyman 1 Francesco Muntoni 6 Stephen O'Rahilly 5 Alexandros Onoufriadis 3 Felicity Payne 1 Vincent Plagnol 9 Lucy Raymond 10 David B. Savage 5 Peter J. Scambler 3 Miriam Schmidts 3 Nadia Schoenmakers 5 Robert Semple 5 Eva Serra 1 Jim Stalker 1 Margriet van Kogelenberg 1 Parthiban Vijayarangakannan 1 Klaudia Walter 1 Ros Whittall 8 Kathy Williamson 7 1 The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1HH, Cambridge, UK. 2 Department of Pathology, King Abdulaziz Medical City, Riyadh, Saudi Arabia. 3 Molecular Medicine Unit and Birth Defects Research Centre, UCL Institute of Child Health, London, WC1N 1EH, UK. 4 Department of Cardiovascular Medicine and Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford, OX3 7BN, UK. 5 University of Cambridge Metabolic Research Laboratories, and NIHR Cambridge Biomedical Research Centre, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK. 6 Dubowitz Neuromuscular Centre, UCL Institute of child health & Great Ormond street Hospital, London, WC1N 3JH, UK. 7 MRC Human Genetics Unit, MRC Institute of Genetic and Molecular Medicine, at the University of Edinburgh, Western General Hospital, Edinburgh, EH4 2XU, UK. 8 Cardiovascular Genetics, BHF Laboratories, Rayne Building, Institute Cardiovascular Sciences, University College London, London WC1E 6JJ, UK. 9 University College London (UCL) Genetics Institute (UGI) Gower Street, London, WC1E 6BT, UK. 10 Dept. of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, CB2 2XY, UK. 10